RNA-sequencing of IDH-wild-type glioblastoma with chromothripsis identifies novel gene fusions with potential oncogenic properties

Franck Ah-Pine a, Déborah Casas b, Philippe Menei c, Blandine Boisselier a,b, Emmanuel Garcion b, Audrey Rousseau a,b,c,⁎

a Département de Pathologie Cellulaire et Tissulaire, CHU Angers, 4 rue Larrey, 49100 Angers, France
b CRCINA, INSERM, Université de Nantes, Université d’Angers, 4 rue Larrey, 49100 Angers, France
c Département de Neurochirurgie, CHU Angers, 4 rue Larrey, 49100 Angers, France

ARTICLE INFO

Article history:
Received 18 June 2020
Received in revised form 16 September 2020
Accepted 21 September 2020

ABSTRACT

Glioblastoma (GBM) is the most frequent and most aggressive form of glioma. It is characterized by marked genomic instability, which suggests that chromothripsis (CT) might be involved in GBM initiation. Recently, CT has emerged as an alternative mechanism of cancer development, involving massive chromosome rearrangements in a one-step catastrophic event. The aim of the study was to detect CT in GBM and identify novel gene fusions in CT regions. One hundred and seventy IDH-wild-type GBM were screened for CT patterns using whole-genome single nucleotide polymorphism (SNP) arrays. RNA sequencing was performed in 52 GBM with CT features to identify gene fusions within CT regions. Forty tumors (40/52, 77%) harbored at least one gene fusion within CT regions. We identified 120 candidate gene fusions, 30 of which with potential oncogenic activities. We validated 11 gene fusions, which involved the most recurrent fusion partners (EGFR, SEPT14, VOPP1 and CPM), by RT-PCR and Sanger sequencing. The occurrence of CT points to underlying gene fusions in IDH-wild-type GBM. CT provides exciting new research avenues in this highly aggressive cancer.

Introduction

Gliomas are the most frequent primary tumors of the central nervous system (CNS) [1]. More than half of gliomas are glioblastomas (GBM), which represent the most common and most aggressive form of glial tumors (WHO grade IV) [2]. Over 90% of GBM are primary (de novo) tumors, arising without a past history of lower-grade diffuse glioma, whereas secondary GBM results from the progression of a lower-grade diffuse glioma. Primary GBM develop rapidly, often in older patients (>55 years-old), and are associated with a shorter survival compared to secondary GBM (median overall survival 15 months vs 2–3 years) [2]. The physiopathogenesis of GBM is still unknown. GBM harbor genomic instability with numerous copy number alterations (CNA); the most common chromosomal imbalances are gain of chromosome (chr) 7 and loss of chr 9p and 10. Primary GBM typically display EGFR amplification (and/or chr 7 gain), PTEN mutation or homozygous deletion, TERT promoter mutation, CDKN2A homozygous deletion, and chr 10 loss [3–6]. Secondary GBM harbor, in most cases, isocitrate dehydrogenase 1 or 2 (IDH1/2) gene mutation, the earliest genetic event known in gliomagenesis and one of the most potent predictors of longer survival [7,8].

The genomic complexity observed in GBM has suggested CT as a potential mechanism of GBM initiation. Contrasting with the conventional (incremental, step-by-step) model of cancer development, CT is a single catastrophic phenomenon (punctuated equilibrium) by which one or a few chr are shattered into tens to hundreds of pieces randomly reassembled by the DNA repair machinery [9,10] (Supplementary file 1). This one-step event may lead to the loss of tumor suppressor genes, the gain and/or amplification of oncogenes, and/or the formation of oncogenic gene fusions [9]. CT has been shown to occur in 8.7% of cancers, such as breast, ovarian, lung or colon adenocarcinomas, and in over a third (38.9%) of GBM [11–13]. This catastrophic event might be involved in the pathogenesis of aggressive fast-growing tumors, such as IDH-wild-type GBM, which are additionally
characterized by numerous chr aberrations. However, it is still unclear whether CT is a cause or a consequence of the dramatic chr instability observed in some tumors.

Gene fusions result from the juxtaposition of two genes during chr rearrangements that may lead to the expression of a chimeric protein. Since the Philadelphia chr (BCR-ABL1 gene fusion resulting from a translocation t(9;22)) has been identified as a key genetic alteration and therapeutic target (of imatinib mesylate) in chronic myeloid leukemia, detection of such potent driver gene fusions has been of great interest in cancer research [14]. Deep sequencing technologies have allowed the identification of gene fusions in hematological neoplasms, sarcomas, carcinomas, but also CNS tumors, including GBM [15–17]. The first oncogenic gene fusion reported in GBM was the FIG-ROS1 fusion in 2003 [18]. The EGRF-SEPT14 fusion has been observed in 4% of GBM [19]. The FGFR3-TACC3 fusion has been detected in 3% of GBM with promising therapeutic effects of FGFR inhibitors on these tumors [20,21]. In this context, CT provides novel insights into GBM pathogenesis and exciting new research avenues for the identification of targetable driver gene fusions.

Our study aimed to identify oncogenic gene fusions within CT regions in a cohort of 170 adult IDH-wild-type GBM. We identified CT patterns by whole-genome SNP arrays and performed RNA sequencing (RNA-seq) to detect novel gene fusions within CT regions. We selected gene fusions involving recurrent partners with potential oncogenic properties and validated the candidate fusions by RT-PCR followed by Sanger sequencing. Eleven potential oncogenic gene fusions were thus identified.

Material and methods

Patients and tumor samples

We selected 170 cases from the registries of the Pathology Department for which a diagnosis of GBM was made between 2005 and 2017. All cases met the following criteria: 1) histopathological diagnosis of IDH-wild-type GBM according to the 2016 WHO classification, 2) age at diagnosis >18 years-old, 3) available fresh frozen tissue containing at least 60% of tumor cells, and 4) written informed consent from each patient and approval of the research ethics committees of Angers University Hospital (Comité de Protection des Personnes, n° CP CB 2015/08). Frozen samples were retrieved from Angers University Hospital Biobank (CRB, biological resource center).

SNP array and copy number analyses

Tumor DNA of 170 frozen samples was extracted using the Nucleospin Tissue Kit (Macherey Nagel) and quantified using Qubit dsDNA BR Assay Kit (Life Technologies). Tumor DNA was hybridized with Infinium CytoSNP-850 K Illumina Beadchips (Illumina) according to the manufacturer's instructions. SNP arrays were scanned on an iScan (Illumina) and data were processed using the genotyping module in Genome Studio v2011.1 (Illumina) to calculate the B-allele frequencies (BAF) and logR ratios. The GAP method was used to call somatic DNA and assess the ploidy for each tumor [22,23].

CT identification

CT events were detected using segmented data (LogR ratio, BAF value) from SNP arrays, following the three major criteria described by Korbel and Campbell [24]:

1) There were at least ten genomic rearrangements per chr arm with such rearrangements occurring in no more than four chr in a given sample,
2) There was a clustering of breakpoints,
3) There was interspersed loss and retention of heterozygosity with no more than two to three different copy number states (except for focal amplification or homozygous deletion (involving key cancer genes)).

After a manual screening, according to the criteria mentioned above, a validation analysis was performed on segmented data using CILPScanner, a web server for the detection of CT patterns [25].

1.1. RNA extraction and sequencing

Total RNA from tumor samples in which CT had been detected was extracted and purified using RNeasy Lipid Tissue Mini Kit (Qiagen) according to the supplier's recommendations. Evaluation of the total RNA for quantity and purity was performed using Nanodrop ND-1000 spectrophotometer (Thermo Fisher Scientific). Library preparation and sequencing were performed by Integenx high-throughput sequencing platform. Briefly, the libraries were prepared with the TruSeq Stranded mRNA kit following the manufacturer’s protocol and sequencing of the cDNA libraries was carried out using an Illumina HiSeq4000 with a 75-bp paired-end read length.

Bioinformatic analyses

The quality of the reads was evaluated for each sample using FastQC (V.0.11.4; http://www.bioinformatics.babraham.ac.uk/projects/fastqc/) and RNA-SeqQC [26]. Alignment was performed by STAR (V.2.5; https://github.com/alexdobin/STAR). To detect candidate gene fusions in RNA sequencing data, we used FusionCatcher (V.0.99.7c; Start with fastq files) and Star-Fusion (V.0.8.0; Start with alignment files). In silico validation of predicted fusion transcripts was performed by FusionInspector (https://github.com/FusionInspector/FusionInspector). The candidate gene fusions were annotated according to 1) a list of known false positives (1000G, chimerdb2, gtex), 2) databases of known gene fusions found in healthy individuals, and 3) cancer databases (cosmic and 18cancers). EGFRvIII rearrangement (exon 2–7 skipping of EGFR gene) was identified by manual review of RNAseq data.

Potential oncogenic gene fusions were selected when any predicted in-frame fusion involved at least one partner with a potential or well-known role in cancer. For the selection of oncogenic fusion partners, we used Oncoscore (V.1.12.0, https://github.com/danro9685/OncoScore), a bioinformatic tool that measures the association of genes to cancer based on citation frequencies in biomedical literature (Oncoscore cut-off threshold = 21.09 according to the developer’s recommendations and published data) [27]. Any gene involved in a predicted in-frame gene fusion was evaluated by the Oncoscore algorithm. The exact role of the potentially cancer-related genes identified (Oncoscore >21.09) was thoroughly checked manually on PubMed.

Circos plot were created with Circos (http://omgenomics.com/circos/). Fusion transcripts and putative derived chimeric proteins were visualized using chimeraviz (V1.8.5, https://github.com/stianlagstad/chimeraviz) and AGFusion (V.1.251, https://github.com/murphyj/AGFusion) [28,29].

Expression levels of transcripts were measured with FPKM normalization method using Stringtie software (V.1.3.6, https://github.com/gpertea/stringtie).

Gene fusion validation

Briefly, 500 ng of total tumor RNA was retrotranscribed using the Maxima First Strand cDNA Synthesis Kit for RT-qPCR kit (Thermo Fisher scientific) following the manufacturer’s instructions. Synthesized single-stranded cDNA was amplified using forward and reverse primer combinations, which were designed within the margins of the paired-end read sequences detected by RNA-seq (Supplementary file 2). Direct Sanger sequencing of cDNA products was performed to confirm the DNA sequence and translation frame.

Statistical analyses

Statistical analyses were performed using GraphPad Prism version 7.0 for MacOS, GraphPad Software (www.graphpad.com). Fisher’s exact probability test was used to analyze the association of EGFR amplification, MDM2 and/or CDK4 amplification and CDKN2A homozygous deletion.
Fig. 1. Landscape of copy number alterations in 170 IDH-wild-type GBM. Whole chr losses are in dark green, partial losses in light green, chr gains in red (which were mostly whole chr gains) and copy neutral loss of heterozygosity (LOH) in light blue. Amplifications and homozygous deletions of key cancer genes in GBM are shown in orange and CT is shown in dark blue. Chr: chromosome; CT: chromothripsis. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
with CT (p-value: 0.12 (ns), 0.033 (*), 0.002 (**), <0.001 (***)). The statistical significance of FPKM differences observed between groups with and without CT was assessed by Mann-Whitney tests (p-value: 0.12 (ns), 0.033 (*), 0.002 (**), <0.001 (***)).

Results

Patient and tumor characteristics

The median age of the 170 patients at diagnosis was 61 years-old (range: 22–84). The male-to-female ratio was 1.39. Chromosome imbalances, gene amplifications, and homozygous deletions were investigated by SNP arrays (Fig. 1). The most common CNAs were chr 10q loss (153/170, 90%), chr 10p loss (144/170, 84.7%), chr 7q gain (132/170, 77.6%), chr 7p gain (131/170, 77.0%), and chr 9p loss (85/170, 50.0%).

CDKN2A homozygous deletion was the most frequent gene alteration (90/170, 52.9%), followed by EGFR amplification (70/170, 41.2%). MDM2 amplification and CDK4 amplification were found in 19 (19/170, 11.2%) and 24 GBM (24/170, 14.1%), respectively. MDM2 and CDK4 were co-amplified in 17 cases (17/170, 10.0%).

CT is a common phenomenon in IDH-wild-type GBM

To evaluate the frequency of CT in IDH-wild-type GBM, we generated copy number profiles of 170 tumors by SNP arrays to detect CT patterns. Sixty-six cases (66/170, 38.8%) exhibited CT features (Fig. 1). Most glioblastoma cases with CT harbored only one rearranged chromosome (44/66, 66.7%). Glioblastomas harboring 2 chr (14/66, 21.2%), 3 chr (6/66, 9.1%) or 4 chr (2/66, 3.0%) with CT features were less frequent. CT mostly involved chr 7 (26/66, 39.4%), chr 9 (19/66, 28.8%), and chr 12 (12/66, 18.2%) and was associated with EGFR amplification (chr7p11), CDKN2A homozygous deletion (chr9p21) and CDK4/MDM2 co-amplification (chr12q14/12q15), respectively (p < 0.001, Fisher’s exact probability test) (Fig. 2).

CT regions harbor gene fusions in IDH-wild-type GBM

Out of 66 GBM with CT, 14 cases were excluded from RNA-seq because of insufficient tumor material or suboptimal nucleic acid quality or quantity. RNA-seq was performed in 52 GBM with CT features. The mean number of gene fusions was 1.7 per chromosome exhibiting CT features and 0.27 per chromosome without CT features (p < 0.001, Mann-Whitney test). Putative gene fusions were identified within CT regions (Supplementary files 2 and 3). Gene fusions were mostly the results of intrachromosomal rearrangements (109/120, 90.8%) rather than interchromosomal (11/120, 9.2%) rearrangements (Supplementary file 3). We detected at least one fusion transcript in 40 cases (40/52, 76.9%) and at least one in-frame gene fusion in 30 cases (30/52, 57.7%). The mean number of gene fusions and predicted in-frame fusion transcripts observed per tumor was 2.5 (range: 0–9) and 1.1 (range: 0–5), respectively. Further analysis allowed the identification of 30 in-frame fusions with potential oncogenic activities in 22 GBM (22/52, 42.3%) (Figs. 3 and 4, Supplementary file 2). EGFR was the most recurrent partner.

Fig. 2. Chromothripsis occurrence across the genome in 170 IDH-wild-type GBM. A. CT mostly involved chr 7, 9 and 12. B. EGFR amplification was more frequent in cases with CT on chr 7 compared to cases without CT on chr 7 (22/26, 84.6% vs 49/144, 34.0%, p < 0.001). C. CDKN2A homozygous deletion was more frequent in cases with CT on chr 9 compared to cases without CT on chr 9 (18/19, 94.7% vs 79/151, 52.3%, p < 0.001). D. Amplification of MDM2 and/or CDK4 were more frequent in cases with CT on chr 12 compared to cases without CT on chr 12 (12/12, 100.0% vs 14/158, 8.9%, p < 0.001). Exact Fisher test; p-value: 0.12 (ns), 0.033 (*), 0.002 (**), <0.001 (***)
involved in potential oncogenic fusions (5/52, 9.6%), and EGFR-SEPT14 and EGFR-VSTM2A were the most frequent fusions detected (two occurrences each). No other recurrent gene fusion was observed, but, aside from EGFR, the most recurrent putative oncogenic partners were SEPT14 (4/52, 7.7%), VOPP1 (3/52, 5.8%) and CPM (3/52, 5.8%) (see below). Candidate gene fusions involving recurrent partners were validated by RT-PCR followed by Sanger sequencing (Table 1).

**IDH-wild-type GBM with CT harbor recurrent EGFR fusions**

The EGFR (n = 5) involved three different gene partners: SEPT14 (2/52, 3.8%), VSTM2A (2/52, 3.8%) and VOPP1 (1/52, 1.9%). All five cases also harbored an EGFR gene amplification but lacked the EGFRvIII rearrangement (Supplementary file 4). We evaluated whether an EGFR fusion had a direct influence on EGFR FPKM values, which schematically reflect the expression levels of EGFR transcripts from RNA-seq analysis. EGFR FPKM values were not significantly different in EGFR-amplified tumors whether or not there was an additional EGFR fusion (Mann-Whitney test; p-value: 0.69).

Further analysis of the EGFR fusion transcripts showed that the EGFR-SEPT14 gene fusions (n = 2) and the EGFR-VOPP1 gene fusion (n = 1) shared the same breakpoint within EGFR; they both coded for the N-terminal portion of EGFR (982 residues), including the tyrosine kinase domain, fused respectively with a coiled-coil domain from SEPT14 and a transmembrane helical domain from VOPP1 (Supplementary file 5). The EGFR-VSTM2A gene fusions (n = 2) shared the same breakpoint within EGFR; they involved the N-terminal portion of EGFR, including only 29 residues that would not allow the potential chimeric protein to have EGFR signaling activities. The N-terminal portion of EGFR was fused with the C-terminal portion (210 residues) of the non-oncogenic VSTM2A protein (Supplementary file 5).

**CPM, VOPP1 and SEPT14 are recurrent fusion partners within CT regions in IDH-wild-type GBM**

Three patients had a gene fusion involving carboxypeptidase M (CPM) gene and either MDM2, CPA6, or LEMD3 gene (3/52, 5.8%). They partially involved the peptidase domain of CPM (Fig. 5). The CPM-MDM2 transcript fusion comprised the C-terminal portion of MDM2 (492 residues) that includes the p53 interaction domain (Fig. 5).

Three gene fusions involved VOPP1 gene and either EGFR, SEPT14, or ABCA13 gene. The EGFR-VOPP1 gene fusion has been discussed above. We identified a VOPP1-SEPT14 fusion transcript, coding for the first 18 residues of VOPP1 fused with the C-terminal portion of SEPT14 that includes part of its GTP-binding septin domain (Fig. 5). We detected a VOPP1-ABCA13 fusion transcript retaining the same N-terminal portion of VOPP1 fused with a large C-terminal portion of the non-oncogenic ABCA13 protein (Fig. 5).

**SEPT14 gene fusions were identified in 4 GBM (4/52, 7.7%). The EGFR-SEPT14 (2/52, 3.8%) and VOPP1-SEPT14 fusions have been discussed above. The BLVRA-SEPT14 fusion transcript we detected coded for the N-terminal portion of the non-oncogenic BLVRA protein fused with the C-terminal portion of SEPT14 (514 residues) that includes its whole septin domain (Fig. 5).**

**Discussion**

In most cancers, genomic rearrangements are thought to occur in a step-wise manner during tumor development [10]. Recent findings suggest CT as an alternative mechanism, involving massive chr rearrangements in a one-step catastrophic event [9]. By generating copy number profiles from 170 primary IDH-wild-type GBM by SNP arrays, we showed that up to 38.8% of these tumors exhibited CT features, which is consistent with previously published data [11,12]. Because CT may lead to gene fusions, we analyzed RNA-seq data from primary GBM harboring CT patterns and successfully detected potential oncogenic fusions within CT regions. Overall, RNA-seq performed in 52 GBM led to the identification of 30 putative oncogenic gene fusions, 11 of which were validated by RT-PCR followed by Sanger sequencing. Most cases with CT harbored only one rearranged chromosome which implies that intra-chromosomal rearrangements are more frequent compared to inter-chromosomal rearrangements. Intra-chromosomal rearrangements may be facilitated by spatial proximity of the fusion partners. Interestingly, the candidate gene fusions we identified within a given CT region were not observed in glioblastomas without CT in that region. The identification of driver gene fusions may help understand tumor pathogenesis and open new therapeutic avenues. Singh et al. first reported FGFR3-TACC3 fusions in 3% of GBM [20]; such fusions confer sensitivity to FGFR inhibitors with promising preliminary results in the clinic [30,31]. Herein, we selected any predicted in-frame fusion involving at least one partner with a potential or well-known role in cancer. The gene fusions that we have identified have never been reported previously, except for the EGFR-SEPT14 gene fusion.

EGFR amplification is the most common gene alteration in IDH-wild-type GBM, detected in 40% of the cases [32]. EGFR was the most recurrent fusion partner in our series (5/52, 9.6%) and all EGFR fusions co-occurred with CT at 7q11. This is consistent with the work of Frattini et al. who
Fig. 4. Identification of 30 putative in-frame oncogenic gene fusions within CT regions in 22 IDH-wild-type GBM. Chromosomes are represented in blocks in the inner ring. The outer ring indicates the names of the genes. Putative in-frame oncogenic fusions are represented by arcs joining the two fusion partners. Extensive inter- or intra-chromosomal rearrangements may lead to the formation of oncogenic fusions. Putative in-frame gene fusions within CT regions that involved at least one partner with potential or well-known oncogenic properties were selected.

Table 1
Potential oncogenic fusions involving recurrent partners in CT regions.

| Sample | Gene fusion          | Gene 1 | Chr | Position  | Gene 2 | Chr | Position  |
|--------|----------------------|--------|-----|-----------|--------|-----|-----------|
| 28     | EGFR-VSTM2A          | EGFR   | 7   | 55,087,058| VSTM2A | 7   | 54,612,315|
| 56     | EGFR-VSTM2A          | EGFR   | 7   | 55,087,058| VSTM2A | 7   | 54,544,622|
| 73     | EGFR-SEPT14          | EGFR   | 7   | 55,268,106| SEPT14 | 7   | 55,796,092|
| 123    | EGFR-SEPT14          | EGFR   | 7   | 55,268,106| SEPT14 | 7   | 55,863,785|
| 15     | EGFR-VOPP1           | EGFR   | 7   | 55,268,106| VOPP1  | 7   | 55,521,130|
| 95     | VOPP1-SEPT14         | VOPP1  | 7   | 55,639,964| SEPT14 | 7   | 55,886,916|
| 105    | VOPP1-ABCA13         | VOPP1  | 7   | 55,639,964| ABCA13 | 7   | 48,266,859|
| 109    | BLVRA-SEPT14         | BLVRA  | 7   | 43,840,171| SEPT14 | 7   | 55,914,330|
| 144    | LEMD3-CPM            | LEMD3  | 12  | 65,171,118| CPM    | 12  | 68,885,889|
| 38     | CPM-MDM2             | CPM    | 12  | 69,326,658| MDM2   | 12  | 69,202,988|
| 59     | CPA5-CPM             | CPA6   | 8   | 68,396,003| CPM    | 12  | 69,279,669|

Eleven gene fusions involving recurrent oncogenic partners (EGFR, SEPT14, VOPP1 and CPM) were selected and validated by RT-PCR followed by Sanger sequencing. EGFR was the most recurrent partner involved in potential oncogenic fusions (5/52, 9.6%), followed by SEPT14 (4/52, 7.7%), VOPP1 (3/52, 5.8%), and CPM (3/52, 5.8%).
reported EGFR fusions in 7.6% of GBM (but CT was not studied) [19]. Moreover, we observed an EGFR-SEPT14 fusion in 3.8% of GBM. Frattini et al. reported this fusion in 3.2% (6/185) of GBM and additionally demonstrated that such fusions confer sensitivity to EGFR inhibitors [19]. We showed that EGFR-SEPT14 and EGFR-VOPP1 gene fusions shared the same breakpoint within EGFR that had previously been described in the literature [19,33]. Our results suggest that EGFR-SEPT14 and EGFR-VOPP1 may have similar biological activities. Herein, we demonstrate that fusions involving EGFR may be the results of CT in GBM.

CPM fusions, detected in 5.8% of GBM (3/52), might be potential driver events. CPM gene is located at the multi-aberration 12q13–15 locus [34]. Although few data are available, CPM is an extracellular membrane-bound peptidase that cleaves the C-terminal arginine of epidermal growth factor (EGF), resulting in des-Arg-EGF which binds EGFR with equal or higher affinity than native EGF [35]. It is not known whether CPM modulates EGFR signaling but CPM was recently identified as a recurrently amplified gene in liposarcoma and a potential oncogene involved in EGFR signaling in vitro and in vivo (murine xenograft model) [36]. Kanojia et al.
showed that CPM knockdown in liposarcoma xenograft significantly decreased tumor growth in vivo [36]. Since our results suggest that CPM fusion and EGFR amplification might be mutually exclusive events (3 cases with CPM fusion that constantly lacked EGFR amplification), we hypothesize that CPM fusions might constitute an alternative mechanism of EGFR activation in a subset of IDH-wild-type GBM. Nonetheless, it is important to mention that CPM gene fusions partially retained the peptide domain of CPM and that MDM2 and/or CDK4 amplification consistently co-existed with CPM fusions. CPM fusions may be bystander events in GBM. Further investigations are needed to define the exact role of CPM fusions in gliomagenesis, independently of MDM2 and/or CDK4 amplification.

SEPT14, a recurrent fusion partner in our series (4/52, 7.7%), belongs to the septin family, comprised of Ras-like GTPases known to be involved in tumorigenesis [37]. Although septins seem to play a role in mechanisms such as proliferation, resistance to apoptosis, cell migration and invasion, a direct relationship between septins and tumorigenesis has yet to be established [37]. Hence, BLVRA-SEPT14 was the only gene fusion that entirely retained the SEPT14 GTPase domain and its C-terminal coiled-coil domain, potentially leading to a chimeric protein with the putative oncogenic functions of SEPT14.

VOPP1 was identified as a potential oncogenic fusion partner. It is a frequently EGFR-complained gene (amplified in at least one-third of EGFR-amplified GBM) that has been shown to be a key regulator of NF-kb signaling and to contribute to resistance to apoptosis [38]. However, in our series, gene fusions involving VOPP1 did not preserve the functional domains of VOPP1 and thus, might not be considered as oncogenic.

First described by Stephens et al. in 2011, CT is a catalytic phenomenon whose detection, among complex chr rearrangements, is still challenging [9]. The criteria of CT, as defined by Korbel and Campbell, were historically based on whole-genome paired-end DNA sequencing data. They include 1) clustering of breakpoints, 2) regularity of oscillating copy-number states, 3) prevalence of regions with interspersed loss and retention, 4) prevalence of rearrangements affecting a single haplotype, 5) randomness of DNA fragment sizes, 6) randomness of DNA fragment order, and 7) ability to walk the derivative chr [9,24]. Herein, CT patterns were investigated by SNP arrays, which allow the detection of the major (first three) features of CT according to this definition [9,24]. As suggested by Korbel and Campbell, the diagnostic criteria must be considered as part of an evolving definition. For instance, for Stephens et al., at least 50 breakpoints per chr should be present but many publications used less stringent criteria, with a threshold of 5 to 20 breakpoints per chr [15,39–41]. Herein, we chose a threshold of 10 breakpoints per chr arm, as most authors did [15,39–42,45]. Using statistical simulation, Kinsella et al. pointed out how challenging CT identification and its distinction from “CT-like events” (which may result from sequential rearrangements) might be [46]. This emphasizes the need for further investigations to refine the diagnostic criteria for CT [46]. Nonetheless, in our study, a subset of GBM harbored chr that had undergone complex genomic rearrangements highly suggestive of CT [9,24]. Studies on larger cohorts are needed in order to confirm our results and potentially identify a recurrent gene fusion (apart from the already known EGFR-SEPT14 fusion) rather than a recurrent partner. At this point, it is, however, difficult to state if the lack of recurrence is due to the relatively small size of our cohort or the random dimension of CT, which by definition reassembles shattered chr haphazardly. Last but not least, we selected potential oncogenic fusion genes based on Oncoscore (measurement of the association of genes to cancer based on citation frequencies in the literature). The relevance of the gene fusions identified needs to be assessed through functional studies. Lentiviral transduction of human (glioblastoma or glioma) cell lines would allow assessment of proliferation and migration of cells expressing the fusion gene. Investigating the downstream signaling pathways and the potential sensitivity to specific inhibitors would provide answers as to the role of the gene fusions in GBM.

The exact mechanisms of CT are yet to discover. The most common hypothesis relies on the formation of a micronucleus, which is a consequence of chr segregation errors during mitosis (especially in cells deficient in the p53 checkpoint). Mis-segregated chr become encapsulated into micronuclei with fragmentation of the trapped chr during the following mitosis [47]. Chr pulverization and subsequent non-homologous end-joining (NHEJ)-mediated repair lead to inter- and intra-chromosomal rearrangements and genomic instability [48,49]. Rausch et al. demonstrated an association between TP53 mutation and CT occurrence in Sonic Hedgehog medulloblastoma and acute myeloid leukemia [39]. Herein, our results do not suggest such an association since only 17.3% (9/52) of GBM with CT harbored a TP53 mutation.

In conclusion, CT points to underlying gene fusions in IDH-wild-type GBM. CT detection should incite searching for gene fusions in GBM patients. The functional relevance of CT-related fusions has yet to be demonstrated. Introduction of the fusion genes into cell lines using lentiviral vectors may be a way to assess the potential oncogenic functions of the fusions. Showing enhanced cell proliferation or migration would get scientists and clinicians one step closer to understanding the role of the gene fusions in GBM.

Supplementary data to this article can be found online at https://doi.org/10.1016/j.tranon.2020.100884.

Funding

This work was supported by a grant from La Ligue Contre le Cancer 44, 45 and 49.

CRediT authorship contribution statement

Franck Ah-Pine: Conceptualization, Formal analysis, Investigation, Writing – Original Draft, Visualization
Déborah Casas : Conceptualization, Investigation, Validation, Writing - Review & Editing
Philippe Menei : Resources
Blandine Boisselier: Conceptualization, Methodology, Investigation, Validation, Formal analysis, Writing - Review & Editing
Emmanuel Garcion: Conceptualization, Methodology, Supervision, Project administration, Writing- Review & Editing
Audrey Rousseau: Conceptualization, Methodology, Supervision, Project administration, Funding acquisition, Writing - Review & Editing

Declaration of competing interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

References

[1] Q.T. Ostrom, H. Gittleman, P. Liao, T. Vecchione-Koval, Y. Wolinsky, C. Kruchko, J.S. Barnholtz-Sloan, CBTRUS statistical report: Primary brain and other central nervous system tumors diagnosed in the United States in 2010–2014, Neuro-Oncology 19 (2017) v1–v88, https://doi.org/10.1093/neurooncology/foxz58.
[2] D.N. Louis, H. Ogbuki, O. Wiestler, W. Cavenee, WHO Classification of Tumours of the Central Nervous System, International Agency For Research On Cancer http://publications.iarc.fr/Book-and-Report-Series/WHO-IARC-Classification-of-Tumours/WHO-Classification-of-Tumours-of-the-Central-Nervous-System-2016-2016. (Accessed 18 November 2017).
[3] H. Fujitawa, R.M. Reis, M. Nakamura, S. Colella, Y. Yonekawa, P. Kleihues, H. Ogbuki, Loss of heterozygosity on chromosome 10 is more extensive in primary (de novo) than in secondary glioblastomas, Lab. Invest. 80 (2000) 65–72, https://doi.org/10.1038/ labinvest.378009.
[4] H. Ogbuki, P. Kleihues, Genetic pathways to primary and secondary glioblastoma, Am. J. Pathol. 170 (2007) 1445–1453, https://doi.org/10.2353/ajpath.2007.070011.
[5] R. Mclendon, A. Friedman, D. Bigner, E.G. Van Meir, D.J. Brat, G.M. Mastrogianakis, J.J. Olson, T. Mikkelson, N. Lehman, K. Aldape, W.K. Alfred Yang, O. Bogler, S. VandenBerg, M. Berger, M. Prados, D. Munzy, M. Morgan, S. Scherer, A. Sabo, L. Nazareth, L. Lewis, O. Hall, Y. Zhu, Y. Ren, O. Alvi, J. Yao, A. Hawes, S. Jhangiani, G. Fowler, A. San Lucas, C. Kovar, A. Cree, H. Dinh, J. Santibanez, V. Joshi, M.L. Gonzalez-Garay, C.A. Miller, A. Milosavljevic, L. Donehower, D.A. Wheeler, R.A. Gibbs, K. Cibulskis, C. Sougnez, T. Fennell, S. Mahan, J. Wilkinson, L. Ziaura, R. Onofrio, T. Bloom, R. Nicola, K. Ardill, J. Baldwin, S. Gabriel, E.S. Lander, L. Ding, R.S. Fulton, M.D. McLellan, J. Wallis, D.E. Larson, X. Shi, R. Abbott, L. Fulton, K. Chen, D.C. Kokolda, M.C. Wendl, R. Meyer, Y. Tang, L. Lin, J.R. Osborne, B.H. Dunford-Snood, T.L. Miner, K. Ieda,

8
[13] B. Boisselier, F. Dugay, M.-A. Belaud-Rotureau, A. Coutolleau, E. Garcion, P. Menei, P. S.G. O’Brien, F. Guilhot, R.A. Larson, I. Gathmann, M. Baccarani, F. Cervantes, J.J. M. Labussière, B. Boisselier, K. Mokhtari, A.-L. Di Stefano, A. Rahimian, M. Rossetto, P. H. Yan, D.W. Parsons, G. Jin, R. McLendon, B.A. Rasheed, W. Yuan, I. Kos, I. Batinic-Hauser, A.G. Saad, A. Iolascon, S. Jung, C.G. Carlotti, R. Vibhakar, Y.S. Ra, S. Robinson, S. Albrecht, N. Jabado, J.C. Lindsey, S. Bailey, N. Gupta, W.A. Weiss, L. Bognár, A. M.F. Roussel, M. Kool, D.T.W. Jones, H. Witt, A. Fernandez-L, A.M. Kenney, R.J. A. Korshunov, J. Reimand, S.E. Schumacher, R. Beroukhim, D.W. Ellison, C.R. Marshall, M. Guyer, B. Ozenberger, J. Peterson, E. Thomson, Comprehensive genomic characterization of TERT, EGFR, and IDH status de-

[14] Fielding, M.L. Ferguson, C. Schaefer, S. Madhavan, K.H. Buetow, F. Collins, P. Good, Gerald, C. Sander, M. Ladanyi, C.M. Perou, D. Neil Hayes, M.D. Topal, K.A. Hoadley, B.S. Taylor, A. Lash, N. Schultz, B. Reva, Y. Antipin, A. Stukalov, B. Gross, E. Cerami, W. T. Chung, G. Sherlock, J.D. Brooks, R.M. Myers, P.T. Spellman, E. Purdom, L.R. Jakkula, O’Kelly, J. Robinson, G. Alexe, R. Beroukhim, S. Carter, D. Chiang, J. Gould, S. Gupta,

[15] Markowitz, Comparative lesion sequencing provides insights into tumor evolution, Sci. Rep. 7 (2017) 46290,https://doi.org/10.1038/s41598-017-09695-x.

[16] J.M. Furgmann, R.F. Koncar, S.K. Michelaugh, F.H. Sarkar, M. Alt, S.E. Olson, J.-B. Kiser, A. Schneck, L. Hovestadt, V. Cervantes, T. Weatherall, A. Ramírez, T. Degenhardt, Y. Sun, M. Loehnert, C. Morgenstern, D. Beasley, S. Sanders, A. Kahn, R. Stief, J. Chen, D. Nussa, L. Feng, E. Hickey, J. Zhang, J.N. Weinstein, A. Barker, D.S. Gerhard, J. Vockley, C. Compton, J. Vaught, P. Fielding, M.L. Ferguson, C. Schaefer, M. Bartram, K.H. Buetow, C. Collins, F. Collins, P. Good, M. Guyer, B. Ozenberger, J. Peterson, E. Thomson, Comprehensive genomic character-

[17] R.D. Morin, K. Mungall, E. Pleasance, A.J. Mungall, R. Goya, R.D. Huff, D.W. Scott, J. Hartl, J. Reiffers, G. Saglio, J. Shepherd, B. Simonsson, A. Gratwohl, J.M. Goldman, H. Van Meir, M. Prados, A. Sloan, K.L. Black, J. Eschbacher, G. Finocchiaro, W. Friedman, Ciriello, W.K. Yung, W. Zhang, C. Sougnez, T. Mikkelsen, G. Finocchiaro, A. Iavarone, The inte-

[18] K. Taylor, G. Verhoef, A.E. Bolton, R. Capdeville, B.J. Druker, Imatinib combi-

[19] J. Korbel, P.J. Campbell, Massive genomic rearrangements in primary glioblastomas de-

[20] P. Laird, D. Haussler, G. Getz, L. Chin, C. TCGA Research Network, J. Barnholtz-Sloan, R. Penny, R. Kucherlapati, C.M. Perou, D.N. Hayes, R. Gibbs, M. Marra, G.B. Mills, E. Parmigiani, J.P. Northcott, R. Aghamirzaee-Nejad, V. Cervantes, T. Weatherall, A. Ramírez, T. Degenhardt, Y. Sun, M. Loehnert, C. Morgenstern, D. Beasley, S. Sanders, A. Kahn, R. Stief, J. Chen, D. Nussa, L. Feng, E. Hickey, J. Zhang, J.N. Weinstein, A. Barker, D.S. Gerhard, J. Vockley, C. Compton, J. Vaught, P. Fielding, M.L. Ferguson, C. Schaefer, M. Bartram, K.H. Buetow, C. Collins, F. Collins, P. Good, M. Guyer, B. Ozenberger, J. Peterson, E. Thomson, Comprehensive genomic character-

[21] J. Reiffers, G. Saglio, J. Shepherd, B. Simonsson, A. Gratwohl, J.M. Goldman, H. Van Meir, M. Prados, A. Sloan, K.L. Black, J. Eschbacher, G. Finocchiaro, W. Friedman, Ciriello, W.K. Yung, W. Zhang, C. Sougnez, T. Mikkelsen, G. Finocchiaro, A. Iavarone, The inte-

[22] P.J. Gardina, K.C. Lo, W. Lee, J.K. Cowell, Y. Turpaz, Ploidy status and copy number ab-

[23] J. Korbel, P.J. Campbell, Criteria for inference of Chromothripsis in Cancer genomes,

[24] J. Yang, J. Liu, Y. Ouyang, Y. Chen, B. Liu, H. Cai, CTLPScanner: a web server for assessing the oncogenic potential of genes, Sci. Rep. 7 (2017) 46290,https://doi.org/10.1038/s41598-017-09695-x.

[25] J. Yang, L. Ouyang, Y. Chen, B. Liu, H. Cai, CTLPScanner: a web server for assessing the oncogenic potential of genes, Sci. Rep. 7 (2017) 46290,https://doi.org/10.1038/s41598-017-09695-x.

[26] J.A. Slupsky, T. Whittaker, Massive genomic rearrangements as additional signa-

[27] I. Batinic-Hauser, A.G. Saad, A. Iolascon, S. Jung, C.G. Carlotti, R. Vibhakar, Y.S. Ra, S. Robinson, S. Albrecht, N. Jabado, J.C. Lindsey, S. Bailey, N. Gupta, W.A. Weiss, L. Bognár, A. M.F. Roussel, M. Kool, D.T.W. Jones, H. Witt, A. Fernandez-L, A.M. Kenney, R.J. A. Korshunov, J. Reimand, S.E. Schumacher, R. Beroukhim, D.W. Ellison, C.R. Marshall, M. Guyer, B. Ozenberger, J. Peterson, E. Thomson, Comprehensive genomic character-

[28] J. Yang, L. Ouyang, Y. Chen, B. Liu, H. Cai, CTLPScanner: a web server for assessing the oncogenic potential of genes, Sci. Rep. 7 (2017) 46290,https://doi.org/10.1038/s41598-017-09695-x.

[29] C. Murphy, O. Elemento, AGFusion: annotate and visualize gene fusions, BioRxiv.
